CRISPR Breakthrough Revives Chemo Response in Lung Cancer Models, CorriXR Reports
NEWARK, DE — CorriXR Therapeutics announced new peer-reviewed findings showing that its CRISPR-based gene-editing approach can resensitize squamous cell lung carcinoma (LUSC) tumors to standard chemotherapy, offering a potential path …
CRISPR Breakthrough Revives Chemo Response in Lung Cancer Models, CorriXR Reports Read More